{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:40:38Z","timestamp":1763037638674,"version":"3.37.3"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background and aims<\/jats:title>\n<jats:p>Untreated Familial Hypercholesterolemia (FH) leads to premature morbidity and mortality. In France, its epidemiology and management are understudied in ambulatory care. We described the clinical profile, pharmacological management, and clinical outcomes in a French sample of FH patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This was a retrospective longitudinal study on patients from The Health Improvement Network (THIN<jats:sup>\u00ae<\/jats:sup>) database in France, between October 2016-June 2019. Patients \u226518 years, with probable\/definite FH based on the Dutch Lipid Clinic Network (DLCN) criteria were included. Baseline characteristics, lipid profile, lipid-lowering therapy (LLT), low-density lipoprotein-cholesterol (LDL-C) goal achievement; and disease management at 6-month of follow-up were analyzed.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>116 patients with probable (n = 70)\/definite (n = 46) FH were included (mean age:57.8\u00b114.0 years; 56.0% women; 9.5% with personal history of cardiovascular events); 90 patients had data available at follow-up. At baseline, 77.6% of patients had LDL-C&gt;190 mg\/dL, 27.6% were not receiving LLTs, 37.9% received statins alone, 20.7% statins with other LLTs, and 7.7% other LLTs. High-intensity statins were prescribed to 11.2% of patients, 30.2% received moderate-intensity statins, and 8.6% low-intensity statins. Only 6.0% of patients achieved LDL-C goal. At 6-month of follow-up, statins discontinuation and switching were 22.7% and 2.3%, respectively. None of the patients received proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors at baseline nor follow-up.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Despite the existence of effective LLTs, FH patients are suboptimally-treated, do not achieve LDL-C goal, and exhibit worsened pharmacological management over time. Future studies with longer follow-up periods and assessment of factors affecting LDL-C management, including lifestyle and diet, are needed.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0255345","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T17:27:37Z","timestamp":1627925257000},"page":"e0255345","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Screening and treatment of familial hypercholesterolemia in a French sample of ambulatory care patients: A retrospective longitudinal cohort study"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6144-1297","authenticated-orcid":true,"given":"Jean","family":"Ferri\u00e8res","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Banks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetris","family":"Pillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Giorgianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurene","family":"Gantzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beranger","family":"Lekens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaux","family":"Dova-Boivin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Vannak","family":"Chauny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Villa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4636-7361","authenticated-orcid":true,"given":"Gaelle","family":"D\u00e9sam\u00e9ricq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"issue":"22","key":"pone.0255345.ref001","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"SS Gidding","year":"2015","journal-title":"Circulation"},{"issue":"45","key":"pone.0255345.ref002","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society","volume":"34","author":"BG Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"issue":"2","key":"pone.0255345.ref003","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamacardio.2019.5173","article-title":"Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action","volume":"5","author":"Representatives of the Global Familial Hypercholesterolemia Community","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"1","key":"pone.0255345.ref004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ancard.2017.04.015","article-title":"Hypercholest\u00e9rol\u00e9mie familiale: un risque cardiovasculaire largement sous-estim\u00e9","volume":"67","author":"J Ferri\u00e8res","year":"2018","journal-title":"Ann Cardiol Ang\u00e9iologie"},{"issue":"3","key":"pone.0255345.ref005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients","volume":"5","author":"AC Goldberg","year":"2011","journal-title":"J Clin Lipidol"},{"issue":"22","key":"pone.0255345.ref006","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis","volume":"141","author":"P Hu","year":"2020","journal-title":"Circulation"},{"issue":"20","key":"pone.0255345.ref007","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide Prevalence of Familial Hypercholesterolemia","volume":"75","author":"SO Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"pone.0255345.ref008","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cjca.2019.02.013","article-title":"Prevalence and Treatment of Familial Hypercholesterolemia in France","volume":"35","author":"E B\u00e9rard","year":"2019","journal-title":"Can J Cardiol"},{"issue":"2","key":"pone.0255345.ref009","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.acvd.2018.11.007","article-title":"Hypercholesterolaemia and coronary artery disease: A silent killer with several faces","volume":"112","author":"J Ferri\u00e8res","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"key":"pone.0255345.ref010","article-title":"Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels.","author":"V Bianconi","year":"2020","journal-title":"Trends Cardiovasc Med [Internet]"},{"issue":"5","key":"pone.0255345.ref011","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jacl.2016.06.007","article-title":"The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients","volume":"10","author":"S B\u00e9liard","year":"2016","journal-title":"J Clin Lipidol"},{"key":"pone.0255345.ref012","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.atherosclerosis.2018.08.010","article-title":"High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry","volume":"277","author":"S B\u00e9liard","year":"2018","journal-title":"Atherosclerosis"},{"issue":"3","key":"pone.0255345.ref013","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/clc.22881","article-title":"Genetic diagnosis of familial hypercholesterolemia is associated with a premature and high coronary heart disease risk","volume":"41","author":"F S\u00e9guro","year":"2018","journal-title":"Clin Cardiol"},{"issue":"6","key":"pone.0255345.ref014","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.lpm.2013.01.053","article-title":"Diagnostic et traitement des hypercholest\u00e9rol\u00e9mies familiales (HF) chez l\u2019adulte: recommandations de la Nouvelle soci\u00e9t\u00e9 fran\u00e7aise d\u2019ath\u00e9roscl\u00e9rose (NSFA)","volume":"42","author":"M Farnier","year":"2013","journal-title":"La Presse M\u00e9dicale"},{"issue":"22","key":"pone.0255345.ref015","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia","volume":"67","author":"AV Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"pone.0255345.ref016","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ehjqcco\/qcx011","article-title":"Prediction of cardiovascular risk in patients with familial hypercholesterolaemia","volume":"3","author":"G Villa","year":"2017","journal-title":"Eur Heart J\u2014Qual Care Clin Outcomes"},{"key":"pone.0255345.ref017","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/VHRM.S192401","article-title":"Barriers to Early Diagnosis and Treatment of Familial Hypercholesterolemia: Current Perspectives on Improving Patient Care","volume":"16","author":"R Alonso","year":"2020","journal-title":"Vasc Health Risk Manag"},{"key":"pone.0255345.ref018","article-title":"Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia","author":"MP McGowan","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"pone.0255345.ref019","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"F Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"pone.0255345.ref020","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2019.09.015","article-title":"First insights from the EAS familial hypercholesterolaemia collaboration registry: FH is still underdiagnosed and undertreated","volume":"290","author":"J Stock","year":"2019","journal-title":"Atherosclerosis"},{"issue":"nov11 1","key":"pone.0255345.ref021","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"J Versmissen","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"pone.0255345.ref022","article-title":"Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group","volume":"142","author":"HA Neil","year":"1999","journal-title":"Atherosclerosis"},{"issue":"4","key":"pone.0255345.ref023","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1586\/14779072.6.4.567","article-title":"Familial hypercholesterolemia: current treatment and advances in management","volume":"6","author":"R Huijgen","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"11","key":"pone.0255345.ref024","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication","volume":"97","author":"M Benn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0255345.ref025","first-page":"11","volume-title":"European Heart Journal","author":"J Ferri\u00e8res","year":"2016"},{"issue":"10","key":"pone.0255345.ref026","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.acvd.2015.04.003","article-title":"Dutch Lipid Clinic Network low-density lipoprotein cholesterol criteria are associated with long-term mortality in the general population","volume":"108","author":"F S\u00e9guro","year":"2015","journal-title":"Arch Cardiovasc Dis"},{"issue":"25 Part B","key":"pone.0255345.ref027","first-page":"2935","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"DC Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"pone.0255345.ref028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2016.07.007","article-title":"Prevalence of potential familial hypercholesterolemia (FH) in 54,811 statin-treated patients in clinical practice","volume":"252","author":"AL Catapano","year":"2016","journal-title":"Atherosclerosis"},{"issue":"1","key":"pone.0255345.ref029","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2015.04.809","article-title":"Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology","volume":"241","author":"G De Backer","year":"2015","journal-title":"Atherosclerosis"},{"key":"pone.0255345.ref030","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ijcard.2016.08.269","article-title":"What is the actual epidemiology of familial hypercholesterolemia in Italy? Evidence from a National Primary Care Database","volume":"223","author":"V Guglielmi","year":"2016","journal-title":"Int J Cardiol"},{"issue":"2","key":"pone.0255345.ref031","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/MOL.0000000000000496","article-title":"Familial hypercholesterolemia: experience from France","volume":"29","author":"J-P Rab\u00e8s","year":"2018","journal-title":"Curr Opin Lipidol"},{"key":"pone.0255345.ref032","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.atherosclerosis.2018.08.051","article-title":"Overview of the current status of familial hypercholesterolaemia care in over 60 countries\u2014The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","volume":"277","author":"AJ Vallejo-Vaz","year":"2018","journal-title":"Atherosclerosis"},{"issue":"3","key":"pone.0255345.ref033","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/jep.12481","article-title":"Improving detection of familial hypercholesterolaemia in primary care using electronic audit and nurse-led clinics: Diagnosing FH in primary care","volume":"22","author":"the Medway FH Audit Steering Committee","year":"2016","journal-title":"J Eval Clin Pract"},{"issue":"3","key":"pone.0255345.ref034","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.hlc.2014.09.011","article-title":"Systematic Detection of Familial Hypercholesterolaemia in Primary Health Care: A Community Based Prospective Study of Three Methods","volume":"24","author":"AB Kirke","year":"2015","journal-title":"Heart Lung Circ"},{"issue":"2","key":"pone.0255345.ref035","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.atherosclerosis.2014.12.034","article-title":"Improving identification of familial hypercholesterolaemia in primary care: Derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT)","volume":"238","author":"SF Weng","year":"2015","journal-title":"Atherosclerosis"},{"issue":"9","key":"pone.0255345.ref036","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1161\/ATVBAHA.116.307514","article-title":"Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study)","volume":"36","author":"L P\u00e9rez de Isla","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"22","key":"pone.0255345.ref037","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study)","volume":"135","author":"L P\u00e9rez de Isla","year":"2017","journal-title":"Circulation"},{"issue":"9","key":"pone.0255345.ref038","doi-asserted-by":"crossref","first-page":"A606","DOI":"10.1016\/j.jval.2017.08.1176","article-title":"Cardiovascular Disease Risk And Risk Factors Associated With Familial Hypercholesterolemia: A Systematic Review","volume":"20","author":"G Kruse","year":"2017","journal-title":"Value Health"},{"issue":"1","key":"pone.0255345.ref039","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1476-511X-13-65","article-title":"Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort","volume":"13","author":"MD Allard","year":"2014","journal-title":"Lipids Health Dis"},{"issue":"4","key":"pone.0255345.ref040","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.clinthera.2017.03.001","article-title":"Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands","volume":"39","author":"JG Kuiper","year":"2017","journal-title":"Clin Ther"},{"issue":"1","key":"pone.0255345.ref041","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1476-511X-10-94","article-title":"Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART)","volume":"10","author":"N Mata","year":"2011","journal-title":"Lipids Health Dis"},{"issue":"9251","key":"pone.0255345.ref042","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(00)03587-X","article-title":"Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands","volume":"357","author":"MA Umans-Eckenhausen","year":"2001","journal-title":"The Lancet"},{"issue":"7","key":"pone.0255345.ref043","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/pds.730","article-title":"Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients","volume":"11","author":"Y Sik Kim","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0255345.ref044","doi-asserted-by":"crossref","first-page":"i3305","DOI":"10.1136\/bmj.i3305","article-title":"Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database","author":"Y Vinogradova","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"pone.0255345.ref045","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1359105309345170","article-title":"Perceived Risk and Representations of Cardiovascular Disease and Preventive Behaviour in People Diagnosed with Familial Hypercholesterolemia: A Cross-sectional Questionnaire Study","volume":"15","author":"L Claassen","year":"2010","journal-title":"J Health Psychol"},{"issue":"4","key":"pone.0255345.ref046","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00228-013-1640-3","article-title":"Predicting non-adherence in patients with familial hypercholesterolemia","volume":"70","author":"JMH Galema-Boers","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"pone.0255345.ref047","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00019053-200422003-00003","article-title":"Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy","volume":"22","author":"JS Benner","year":"2004","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"pone.0255345.ref048","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data Resource Profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"E Herrett","year":"2015","journal-title":"Int J Epidemiol."},{"issue":"9","key":"pone.0255345.ref049","doi-asserted-by":"crossref","first-page":"e016461","DOI":"10.1136\/bmjopen-2017-016461","article-title":"Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"7","author":"LE Akioyamen","year":"2017","journal-title":"BMJ Open"},{"issue":"9","key":"pone.0255345.ref050","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.amjcard.2008.06.056","article-title":"Comparison of Genetic Versus Clinical Diagnosis in Familial Hypercholesterolemia","volume":"102","author":"F Civeira","year":"2008","journal-title":"Am J Cardiol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T17:28:35Z","timestamp":1627925315000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255345"}},"subtitle":[],"editor":[{"given":"Antonio","family":"Palaz\u00f3n-Bru","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0255345","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2021,8,2]]}}}